1.
Real-world experience of calcipotriene and betamethasone dipropionate foam 0.005%/0.064% in the treatment of adults with psoriasis in the United States.
Wu, JJ, Veverka, KA, Lu, M, Armstrong, AW
The Journal of dermatological treatment. 2019;(5):454-460
Abstract
Background: Clinical trials have established calcipotriene 0.005%/betamethasone dipropionate 0.064% (Cal/BD) foam as a well-tolerated and efficacious topical therapy for psoriasis. Methods: A chart review of 24 US healthcare providers gathered real-world information (clinical characteristics and outcomes, safety, and resource utilization) for patients (≥18 years old) prescribed Cal/BD foam between January 1 and October 31, 2016, along with healthcare provider characteristics and perceptions of Cal/BD foam. Results: Data were reported from 105 patients and 177 active psoriatic lesions. Cal/BD foam was applied once-daily; the prescription was 4 weeks for 69/177 (39%) lesions (median 4, range 1-26 weeks). Knees (n = 41; 23%) and elbows (n = 37; 20%) were the most frequently treated areas. Among 114 lesions, severity improved from "mild"/"moderate"/"severe" to "clear"/"almost clear" in 71%, and 54% had a clinically significant improvement (two-step/greater improvement) in lesion severity from baseline. Of 128 lesions with baseline itch, 90% were not itchy at the best treatment response. Most healthcare providers reported prescribing Cal/BD foam because of its overall efficacy (n = 20/23; 87%). Adverse events were reported in 1/105 patients (1%). Conclusion: Data from real clinical practice demonstrate that Cal/BD foam improves psoriasis disease severity and associated itch in patients and further extend results of clinical trials.
2.
Restoring jawline contour with calcium hydroxylapatite: A prospective, observational study.
Baspeyras, M, Dallara, JM, Cartier, H, Charavel, MH, Dumas, L
Journal of cosmetic dermatology. 2017;(3):342-347
Abstract
BACKGROUND Jawline reshaping by replacing volume has become an indispensable component of modern facial rejuvenation. AIM: To evaluate calcium hydroxylapatite (CaHA) for the treatment of an aging jawline in a routine setting. METHODS Five investigators enrolled 35 subjects requesting jawline rejuvenation with CaHA. Injections were performed according to investigators usual practice. Baseline and post-treatment scores were evaluated using Merz Aesthetics Scales®. Follow-up visits took place at Day 30 (Day 60 for those with touch-up at Day 30), 180, and 360. Physician and patient satisfaction, esthetic impact of treatment, and adverse events were recorded. RESULTS Improvements in jawline contour compared with baseline were statistically significant at each visit, with scores of 2.42 (moderate to severe sagging) at baseline, 1.02 (mild) at Day 30/60 (P≤.0001), 1.11 at Day 180 (P≤.0001), and 1.45 at Day 360 (P=.0015). Statistically significant improvements in marionette line scores were also observed. Investigators rated results as "improved" to "very much improved" in all subjects up to Day 180, and in 81% of subjects at Day 360. Satisfaction with treatment was very high. Adverse events were mostly mild and related to either the procedure or injection technique. CONCLUSION CaHA is a very effective agent for restoring jawline contour in routine practice and is associated with high levels of physician and patient satisfaction.
3.
Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study.
Lambert, J, Hol, CW, Vink, J
Journal of the European Academy of Dermatology and Venereology : JEADV. 2015;(12):2349-55
-
-
Free full text
-
Abstract
BACKGROUND Topical therapies are the mainstay of treatment for psoriasis vulgaris. The fixed combination of calcipotriol (Cal) 50 μg/g plus betamethasone 0.5 mg/g (as dipropionate; BD) is a first-line topical treatment and available as a gel or ointment. The use of these fixed combination products was compared in PRO-long, a long-term noninterventional study, for which interim results (4 and 12 weeks) have previously been reported. OBJECTIVE To describe and compare patients' perspectives on the fixed combination gel and ointment formulations; to include efficacy, adherence behaviour, treatment satisfaction and health-related quality of life (HRQoL) aspects during long-term real-life psoriasis management. METHODS PRO-long was a multicentre, prospective, observational, 52-week study of patients prescribed fixed combination Cal/BD gel or ointment in clinical practice. For final analysis the following were assessed at weeks 24, 36 and 52: differences in the proportion of patients with 'mild'/'very mild' disease according to patient's global assessment of disease severity, adherence behaviour, treatment satisfaction (nine-item treatment satisfaction questionnaire for medication) and HRQoL (Skindex-29). RESULTS Patients (n = 328) were prescribed once-daily Cal/BD gel (n = 152) or ointment (n = 176). At week 52, a higher proportion of patients reported that the severity of their psoriasis was 'mild'/'very mild' vs. baseline (gel: 60.2 vs. 47.1%; ointment: 58.8 vs. 42.4%), with greater treatment satisfaction reported in patients using gel vs. those using ointment. A higher proportion of patients found the gel 'easy' to use compared with the ointment (66.7 vs. 45.2%). Daily application of treatment took ≤ 5 min for 86.1% of patients using gel and 71.0% of patients using ointment. CONCLUSION This real-life study has demonstrated similar effectiveness between the Cal/BD formulations. However, over a 52-week treatment period, patients reported greater treatment satisfaction with the gel, which was considered easier to use, faster to apply and overall a more convenient product.
4.
Evaluation of the effectiveness of a hyperoxidized oil-based medication in the treatment of skin lesions: observational study.
Cassino, R, Ippolito, AM, Cuffaro, P, Corsi, A, Forma, O
Minerva chirurgica. 2015;(1):23-31
Abstract
AIM: Aim of the study was to demonstrate the effectiveness, in the management of recalcitrant wounds, of a hyperoxidized oil-based gel with film-forming and protective functions. METHODS The study involved 50 patients with recalcitrant not infected and/or necrotic chronic ulcers. All patients had 0.7 minimum ABPI value; terminal and/or cancer and/or under immunosuppressive therapy patients were excluded. The dressing consisted in a uniform gel layer applied on the lesion, after cleansing with a 0.05% sodium hypochlorite chloroxidating solution. The dressing was changed every 48 hours (or every 24 hours, in case of hyperexuding wound). The effectiveness was assessed by the evaluation of the WBP score changes and area reduction (via the Visitrak™ Digital System) after an observation period of 4 weeks. RESULTS All patients achieved area improvement; WBP score improved in more than 90% of the B score patients; pain reduction was reported by all patients: more than 55% of the total number of patients limited the use of analgesic drugs and in 6 cases (12%) they discontinued the antalgic therapy. CONCLUSION The dressing showed an actual effectiveness, promoting granulation and accelerating epithelialization; no patient suffered from allergy/intolerance and all of them reported a decrease in pain, until complete relief.